Orlando Scoppetta1, Carlos Arturo Cassiani-Miranda2, Karen Nicolle Arocha-Díaz3, Diego Fernando Cabanzo-Arenas3, Adalberto Campo-Arias4. 1. Universidad Católica de Colombia, Faculty of Psychology, GAEM Group (Research methods applied to behavioral sciences), Bogotá, Colombia. 2. Universidad de Santander, Faculty of Health Sciences, medicine program, Neurosciences Research Group, Bucaramanga, Colombia. Electronic address: ca.cassiani@mail.udes.edu.co. 3. Universidad de Santander, Faculty of Health Sciences, medicine program, Neurosciences Research Group, Bucaramanga, Colombia. 4. Universidad del Magdalena, Faculty of Health Sciences, Health Psychology and Psychiatry Research Group, Santa Marta, Colombia.
Abstract
BACKGROUND: The PHQ-2 is a screening test for major depressive disorder (MDD) derived from PHQ-9, which has shown to be useful in the detection of cases of clinical significance in previous studies. The psychometric properties of PHQ-2 in the Colombian population are unknown. METHODS: PHQ-2 were assessed in 243 patients in general medical consultations using the Mini-International Neuropsychiatric Interview (MINI) as the gold standard. Internal consistency, convergent validity and criterion validity were calculated by analyzing the Receptor Operating Characteristics (ROC) and the area under the curve (AUC). RESULTS: Cronbach's alpha and McDonald's omega coefficients were 0.71. Spearman's rho coefficients for correlations with PHQ-9 and HADS-D scores were 0.63 and 0.59 (p<0.01). AUC was 0.89. The optimal cut point was ≥2 with the following indicators: sensitivity 0.87 specificity 0.74; Youden index 0.60; PPV 0.47; NPV 0.95; (LR+) 3.24; (LR-) 0.18 (95% CI 0.09-0.37). Kappa coefficient between PHQ-2 and MINI for depression was .458 and 0.46 for HADS-D. LIMITATIONS: Since this study was done with people attending hospital, which could has implications for the prevalence of depression, affecting the validity indicators of the instrument. CONCLUSIONS: PHQ-2 show an acceptable test performance in the context of the study. However, the test could yield a considerable amount of false positives that would require specialized evaluation to establish a reliable diagnosis.
BACKGROUND: The PHQ-2 is a screening test for major depressive disorder (MDD) derived from PHQ-9, which has shown to be useful in the detection of cases of clinical significance in previous studies. The psychometric properties of PHQ-2 in the Colombian population are unknown. METHODS: PHQ-2 were assessed in 243 patients in general medical consultations using the Mini-International Neuropsychiatric Interview (MINI) as the gold standard. Internal consistency, convergent validity and criterion validity were calculated by analyzing the Receptor Operating Characteristics (ROC) and the area under the curve (AUC). RESULTS: Cronbach's alpha and McDonald's omega coefficients were 0.71. Spearman's rho coefficients for correlations with PHQ-9 and HADS-D scores were 0.63 and 0.59 (p<0.01). AUC was 0.89. The optimal cut point was ≥2 with the following indicators: sensitivity 0.87 specificity 0.74; Youden index 0.60; PPV 0.47; NPV 0.95; (LR+) 3.24; (LR-) 0.18 (95% CI 0.09-0.37). Kappa coefficient between PHQ-2 and MINI for depression was .458 and 0.46 for HADS-D. LIMITATIONS: Since this study was done with people attending hospital, which could has implications for the prevalence of depression, affecting the validity indicators of the instrument. CONCLUSIONS: PHQ-2 show an acceptable test performance in the context of the study. However, the test could yield a considerable amount of false positives that would require specialized evaluation to establish a reliable diagnosis.
Authors: Saad Thamer Sedeeq; Mohammad Jamil Mohammad AlTamimi; Ehab Hamed; Mohamed Ahmed Syed Journal: Prim Health Care Res Dev Date: 2022-01-31 Impact factor: 1.792
Authors: Carmen Trumello; Sonia Monique Bramanti; Giulia Ballarotto; Carla Candelori; Luca Cerniglia; Silvia Cimino; Monia Crudele; Lucia Lombardi; Silvia Pignataro; Maria Luisa Viceconti; Alessandra Babore Journal: Int J Environ Res Public Health Date: 2020-11-12 Impact factor: 3.390